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Background: T-cell immunoglobulin and mucin domain 3 (TIM-3) is known as a negative immune regulator and
emerging data have implicated TIM-3 a pivotal role in suppressing antitumor immunity. The co-stimulatory receptor
CD137 is transiently upregulated on T-cells following activation and increases their proliferation and survival when
engaged. Although antagonistic anti-TIM-3 or agonistic anti-CD137 antibodies can promote the rejection of several
murine tumors, some poorly immunogenic tumors were refractory to this treatment. In this study, we sought to
evaluate whether combined TIM-3 blockade and CD137 activation would significantly improve the immunotherapy
in the murine ID8 ovarian cancer model.
Methods: Mice with established ID8 tumor were intraperitoneally injected with single or combined anti-TIM-3/CD137
monoclonal antibody (mAb); mice survival was recorded, the composition and gene expression of tumor-infiltrating
immune cells in these mice was analyzed by flow cytometry and quantitative RT-PCR respectively, and the function of
CD8+ cells was evaluated by ELISA and cytotoxicity assay.
Results: Either anti-TIM-3 or CD137 mAb alone, although effective in 3 days established tumor, was unable to prevent
tumor progression in mice bearing 10 days established tumor, however, combined anti-TIM-3/CD137 mAb significantly
inhibited the growth of these tumors with 60% of mice tumor free 90 days after tumor inoculation. Therapeutic
efficacy was associated with a systemic immune response with memory and antigen specificity, required CD4+ cells
and CD8+ cells. The 2 mAb combination increased CD4+ and CD8+ cells and decreased immunosuppressive
CD4+FoxP3+ regulatory T (Treg) cells and CD11b+Gr-1+ myeloid suppressor cells (MDSC) at tumor sites, giving rise to
significantly elevated ratios of CD4+ and CD8+ cells to Treg and MDSC; This is consistent with biasing local immune
response towards an immunostimulatory Th1 type and is further supported by quantitative RT-PCR data showing the
increased Th1-associated genes by anti-TIM-3/CD137 treatment. The increased CD8+ T cells produced high level of
IFN-γ upon tumor antigen stimulation and displayed antigen-specific cytotoxic activity.
Conclusions: To our knowledge, this is the first report investigating the effects of anti-TIM-3/CD137 combined mAb in
a murine ovarian cancer model, and our results may aid the design of future trials for ovarian cancer immunotherapy.Background
Epithelial ovarian carcinoma (EOC) is the leading cause
of death from gynecologic malignancies in the United
States and is the fourth most common cause of cancer
death in women [1]. Over 70% of women with EOC
present with advanced stage disease and tumor dissem-
ination throughout the peritoneal cavity [2]. Despite the* Correspondence: zqg_cmu@163.com
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reproduction in any medium, provided the orstandard therapy with surgical cytoreduction and the
combination of cisplatin and paclitaxel, the treatment ef-
ficacy is significantly limited by the frequent develop-
ment of drug resistance [3]. Novel complementary
strategies are urgently needed to improve the outcomes
of ovarian cancer.
Much data suggest that immunotherapy for EOC
should be effective [4]. Firstly, EOC cells express tumor-
associated antigens against which specific immune re-
sponses have been detected [5-9]. Secondly, the studies
pioneered by Coukos and colleagues indicate tumor. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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EOC supported by the close correlation between survival
and tumor infiltration with CD3+ T cells in the large an-
notated clinical samples [10]. Thirdly, although EOC is a
devastating disease, metastases are frequently restricted
to the peritoneal cavity where the tumor microenviron-
ment is directly accessible, which prevents the need for
systemic delivery of immunostimulatory treatments [11].
Despite the abundant evidence that anti-tumor immun-
ity could be effective, clinical success with immune-
based therapies for EOC has generally been modest [12].
T-cell immunoglobulin and mucin domain 3 (TIM-3),
as a relatively newly described co-inhibitory molecule,
was expressed by IFN-γ–secreting T-helper 1 (Th1) cells
and subsequently on CD8+ T cytotoxic type 1 (Tc1) cells,
DCs and monocytes [13-16]. The galectin-9, a soluble
molecule widely expressed and upregulated by IFN-γ,
was identified as TIM-3 ligand [17,18], which induces
cell death via binding to TIM-3 expressed on Th1 cells
[19], suggesting a role for TIM-3 in negatively regulating
Th1 responses. Emerging data has implicated TIM-3 a
critical role in regulating tumor immune response. Early
studies reported that the growth of 4 T1 mammary tu-
mors was inhibited in TIM-3-deficient mice, and anti-
TIM-3 monoclonal antibody (mAb) could suppress the
growth of established subcutaneous EL4 lymphoma,
suggesting TIM-3 as a potential target for cancer im-
munotherapy [20]. Recent studies observed that the ex-
pression of TIM-3 and PD-1 was up-regulated on
circulating tumor-specific and tumor-infiltrating CD8+ T
cells from patients and mice bearing advanced malignan-
cies respectively, which correlated with the severely
exhausted phenotype defined by failure to proliferate
and produce effector cytokines, and combined blockade
of both TIM-3 and PD-1 pathway reversed tumor-
induced T-cell dysfunction and effectively suppressed
the experimental tumor growth. This finding is further
validated by the experiments demonstrating that com-
bined anti-TIM-3/PD-1 mAbs significantly prevented
established tumor growth and even cured a fraction of
mice in methylcholanthrene-induced fibrosarcomas and 6
different experimental mouse tumor models, supporting
the potential of blocking TIM-3 in combination with other
immune-regulatory mAbs for the treatment of cancer.
CD137 (as known as CD137) belongs to the Tumor
Necrosis Factor Receptor (TNFR) superfamily and is
transiently upregulated on both CD4+ and CD8+ T cells
following activation [21]. Upon engagement, CD137
co-stimulates CD8+ T cells promoting their prolifera-
tion, Th1-type cytokine production, and survival [22].
Much evidence demonstrate the promising effects for
anti-CD137 mAbs in the treatment of mice bearing
established tumors [23,24]; this is not only achieved by
agonist antibodies but also by dimeric RNA aptamersor tumor cells expressing a surface-attached anti-
CD137 single chain antibody [25,26]. This preclinical
evidence has led to clinical trials with 2 human mAbs
directed against CD137 [27].
Although antagonist TIM-3 or agonistic CD137 anti-
bodies can promote the rejection of some murine tumors,
however, poorly immunogenic tumors such as ID8 ovarian
cancer do not respond to antibody therapy alone [28]. We
hypothesized that combined TIM-3 blockade and CD137
activation would strengthen the antitumor effect by syner-
gistically releasing the brake for CD4+ cells and promoting
the function of CD8+ cells. In this study, using ID8 murine
ovarian cancer model, we evaluated the therapeutic effect
of single or combined anti-TIM-3 and anti-CD137 mAbs
and found that combined anti-TIM-3/CD137 significantly
suppressed the 10 days established peritoneal ID8 tumor
growth, resulting in 60% of treated mice tumor free 90 days
after tumor injection. We further characterized the cellu-
lar and molecular mechanisms driving this combined
antitumor effect elucidating the basic processes necessary
to achieve immune-mediated tumor rejection.
Methods
Mice
Female C57BL (6–8 wk old) were purchased from the
Animal Experimental Center of the China Medical
University. Animal use was approved by our institution
(China Medical University).
Cell lines
ID8, a clone of theMOSEC ovarian carcinoma of C57BL/6
origin was a gift from Dr. George Coukos (University of
Pennsylvania, Philadelphia, USA). Murine B16melanoma
cells, TC-1 lung carcinoma cells and T cell lymphoma
EL4 cells were purchased from ATCC (Manassas, VA).
Tumor cells were cultured in the complete DMEM
medium supplemented with 10% FBS (Thermo Scientific,
Rockford, IL), 100 U/mL penicillin and 100 μg/mL
streptomycin before cell suspensions were prepared and
transplanted to mice. The EL4 cells and splenocytes were
maintained in a complete medium of RPMI-1640
supplemented with 10% FBS, 25 mM HEPES, 2 mM glu-
tamine,100U/mLpenicillinand100μg/mLstreptomycin.
Antibodies
Therapeutic anti-CD137 (Clone lob12.3; Catalog#BE0169),
anti-TIM-3 (Clone RMT3-23; Catalog#BE0115), anti-CD4
(Clone GK1.5; Catalog#:BE0003-1), anti-CD8 (Clone 2.43;
Catalog#:BE0061), anti-NK1.1 (Clone PK136; Catalog#:
BE0036), anti-CD19 (Clone 1D3; Catalog#:BE0150) and
control (Clone 2A3; Catalog#:BE0089) were purchased
from BioXcell (West Lebanon, NH). Antibodies used for
flow cytometry were purchased from Tianjing Sungene
(Tianjing, China) and eBioscience (San Diego, CA).
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In the experiments with ID8 ovarian tumor (Additional file 1:
Figure S1), mice (5 or 10 mice/group) were injected
intraperitoneally (i.p.) with 1 × 106 ID8 cells in 0.1 mL
of PBS. At day 3, 7 and 11 (3 days established tumor model)
or days 10, 14 and 18 (10 days established tumor model)
post-tumor injection, each mouse received the i.p. injection
of 250 μg of control, anti-TIM-3, anti-CD137 or combined
anti-TIM-3/CD137 mAb in 250 μL of PBS as shown in the
figure legends. The mice were weighted twice weekly and
checked daily for the clinical sign of swollen bellies indica-
tive of ascites information and for the evidence of toxicity
such as respiratory distress, mobility, weight loss, diarrhea,
hunched posture, and failure to eat while histopathology
was conducted on major organs (i.e., liver, kidney, intes-
tines, lungs, and colon). Following institutional guidelines,
mice were killed when they developed ascites and had a
weight increase > 30%. The survival of each mouse was
recorded and overall survival was calculated.
For assessing the development of immune memory,
pooled (2 independent experiment) 9 long-term surviv-
ing mice (90 days after first tumor injection) from com-
bined anti-TIM-3/CD137 therapy group or age-matched
naïve mice (which served as control) were challenged
i.p. or subcutaneously (s.c.) with 1 × 106 ID8 cells or
1 × 106 syngeneic but antigenically different TC1 cells.
Three perpendicular diameters of s.c. tumors were mea-
sured every second day using a caliper and tumor volumes
were calculated according to the formula: 1/2 × (length) ×
(width)2. Mice were sacrificed when they seemed mori-
bund or their tumors reached 10 mm in diameter.
For depletion of immune cells, mice were injected i.p.
with 500 μg of mAbs to CD8, CD4, NK1.1, or CD19,
1 day before and two days after tumor challenge,
followed by injection of 250 μg every 5 days throughout
the experiment. The efficacy of cell depletion was veri-
fied by staining peripheral blood leukocytes for specific
subsets after depletion (data not shown).
Evaluation of tumor-infiltrating immune cells (TIIC) in
peritoneal lavages by flow cytometry
Mice which had been transplanted i.p. with ID8 cells
were euthanized 7 days after they had been injected with
the 2 mAb combination (or control) as in the therapy
experiments. To obtain peritoneal immune cells, 3 ml
PBS was injected into the peritoneal cavity of mice with
ID8 tumors immediately after euthanasia, their belly was
massaged and the fluid was removed, filtered through a
70 μM cell strainer (BD Biosciences), washed and im-
mune cells were isolated by using a mouse lymphocyte
isolation buffer (Cedarlane, Burlington, Ontario) follow-
ing the manufacturer’s instruction.
For the staining of immune cells, above prepared im-
mune cells were washed with FACS staining buffer andincubated with mouse Fc receptor binding inhibitor
(eBioscience) for 10 minutes before staining with mAbs
(Tianjing Sungene) against mouse CD45 (clone 30-F11),
CD3 (clone 145-2C11), CD4 (clone GK1.5), CD8 (clone
53–6.7), CD19 (clone eBio1D3), CD11b (clone M1/70)
and Gr-1 (clone RB6-8C5) for 30 minutes. For intracel-
lular staining of FoxP3 (clone FJK-16 s; eBioscience),
cells were fixed, permeabilized and stained following the
instruction of Cytofix/Cytoperm kit (BD Bioscience).
Flow cytometry was performed using FACSCalibur (BD
Biosciences) and the data were analyzed using FlowJo
software (Tree Star). All flow cytometry experiments
were performed at least 3 times.Quantitative RT-PCR
Total cellular RNA was extracted using RNeasy Mini Kits
(Qiagen, Hilden, GA) and reverse transcribed into cDNA
using SuperScript III Reverse Transcriptase (Invitrogen).
Expression for genes of interest was analyzed in cells of
peritoneal lavage on day 7 after the third injection of mAb.
The primers for all genes tested, including internal control
GAPDH, were synthesized by Takara Inc., Dalian, China.
Primer sequences were listed in Additional file 2: Table S1.
Quantitative real-time PCR was performed via ABI PRISM
7500 Real-Time PCR Systerm (Applied Biosystems) with
1× SYBR Green Universal PCR Mastermix (Takara). Tran-
script levels were calculated according to the 2–ΔΔCt
method, normalized to the expression of GAPDH, and
expressed as fold change compared with control.Evaluation of antigen-specific CTL immune response
Isolated splenocytes from treated mice were cultured in
the presence of 10 μg/mL H-2Db-restricted mesothelin-
derived peptides (amino acid 406–414) or control HPV-
E7-derived peptide (amino acid 49–57; all from GenScript,
Nanjing, CA) for 3 days. IFN-γ in the supernatants was
determined by Mouse IFN-γ Quantikine ELISA Kit (R&D
systems, Minneapolis, MN).
For CTL assays, effector cells were obtained by
coculturing 5 × 106 splenocytes with 5 × 105 UV-irradiated
ID8 cells for 4 days. Peptide-pulsed EL4 target cells were
generated by adding 10 μg/ml of peptide and incuba-
ting for 4 hours. CTL activity was measured using
the CytoTox96 Non-Radioactive Cytotoxicity Assay kit
(Promega, Madison, WI) following the manufacturer’s in-
structions. In brief, target cells were incubated with vary-
ing numbers of effector cells for about 4 hours, and
supernatants were then analyzed for lactate dehydrogenase
release. The results are expressed as percent specific lysis,
calculated as (Experimental release-Spontaneous release/
Total release-Spontaneous release) × 100. In some experi-
ments, effector cells were incubated with anti-CD4 or
CD8 antibody (10 μg/mL) for 2 hours before CTL assay.
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We detected the presence of mesothelin-specific anti-
bodies using the method described previously [29].
Blood was obtained from 2 mAb treated long-term sur-
viving mice (90 days after the tumor inoculation). The
presence of mesothelin-specific antibodies was deter-
mined by staining the mouse ID8 ovarian cancer cells
using serum from treated mice in a 1:200 dilution,
followed by Phycoerythrin-conjugated anti-mouse IgG
antibody (eBioscience) staining. Staining with sera from
naïve mice was used as negative control. Analysis of cell
staining was performed described above.
ELISA
Mice injected i.p. with 1 × 106 ID8 cells 10 day earlier
were injected thrice at 4 days interval with 250 μg of
control or anti-TIM-3/CD137 mAb. Seven days after the
last mAb injection, pooled peritoneal lavage cells (1 ×
106/well) harvested from treated mice were stimulated
in vitro with 50 ng/ml PMA and 1 μg/ml ionomycin for
6 hours prior to the analysis of IL-10 and IFN-γ produc-
tion in the supernatants by ELISA according to the man-
ual (R&D systems). The results were analyzed after
normalization according to the T cell numbers.
Statistics
Results were expressed as mean ± SEM. All statistical
analyses were performed using GraphPad Prism 5. Stu-
dent’s t test was used to compare the statistical differ-
ence between two groups and one-way ANOVA was
used to compare three or more groups. Survival rates
were analyzed using the Kaplan–Meier method and eval-
uated with the log-rank test with Bonferroni correction.
Significant differences were accepted at p < 0.05.
Results
Synergistic antitumor effect of anti-TIM-3 /CD137 mAb
We tested the antitumor efficacy, defined as prolonged
overall survival, of single or combined anti-TIM-3 and
anti-CD137 mAb in C57BL/6 mice transplanted i.p. 3 or
10 days previously with 1 × 106 ID8 cells. Untreated mice
and mice receiving a control mAb developed ascites
about 30 days post-injection and had to be euthanized
(Additional file 1: Figure S1). As shown in Figure 1A, in
3 days established ID8 tumor model, single injection of
three doses of anti-TIM-3 or anti-CD137 mAb signifi-
cantly prolonged the survival of mice with 20% (1 out of
5 mice) or 40% (2 out of 5 mice) of mice surviving
90 days after tumor injection respectively when the ex-
periment was terminated and euthanized mice were
tumor free in peritoneal cavity, and even mice with
tumor growth had increased mean survival time (MST)
compared with control mAb treated mice (Figure 1C;
MST 30.80, 66.00, 70.67 days for control, anti-TIM-3,anti-CD137 group; p < 0.05, anti-TIM-3 or anti-CD137
mAb compared to control mAb), however, using the same
regimen, these two mAbs individually had little or no ef-
fects on the outgrowth of 10 days established ID8 tumor
leading to ascites formation at the almost same time as
control mAb treated mice. Intriguingly, combined treat-
ment of anti-TIM-3 and anti-CD137 mAbs significantly
increased survival of mice bearing 10 days established
tumor with 60% (6 out of 10 mice) of mice tumor free
90 days after tumor injection (Figure 1B; p < 0.01, com-
bined mAb compared to single or control mAb), and even
mice succumbed to tumor growth also had significantly
prolonged MTS compared with control or single mAb
treated mice (Figure 1D; MTS 31.40, 32.80, 32.50 and
73.00 days for control, anti-TIM-3, anti-CD137 and anti-
TIM-3/CD137 group; p < 0.01, combined mAb compared
to single or control mAb). A repeat of the experiment gave
similar results (data not shown). In addition, combined
anti-TIM-3/CD137 mAbs were even more efficacious in
3 days established ID8 tumor model with 100% of mice
remaining free of tumor 90 days post-injection (Figure 1A;
p < 0.001 compared to control mAb). We did not detect
any expression of TIM-3 and CD137 molecules and their
respective ligands Galectin-9 and CD137L on the surface
of ID8 ovarian cancer cells (data not shown), excluding
the possibility that inhibition of ID8 tumor growth in vivo
is directly mediated by anti-TIM-3 or anti-CD137 mAb.
Notably, those long-term survivors developed the sys-
temic tumor-specific memory immune response in that
they were resistant to the rechallenge by both i.p. and s.
c. injection of ID8 ovarian cancer cells but not s.c. injec-
tion of unrelated TC1 lung cancer cells (Figure 2A)
while naïve mice succumbed to them (Figure 2B). Ninety
days after rechallenge, 100% (3 out of 3 mice) or 66.7%
(2 out of 3 mice) of mice remained tumor-free when
rechallenged with i.p. or s.c. ID8 cells respectively.
Antibody-mediated cell depletion experiments demon-
strated that protection conferred by anti-TIM-3/CD137
mAbs was dependent on the CD4+ and CD8+ T cells as
anti-TIM-3/CD137 mAbs was largely ineffective in the
absence of CD4+ or CD8+ T cells (Figure 2C), but effect-
ive in the absence of mature B cells or NK cells
(Figure 2D).
Combined anti-TIM-3/CD137 mAb treatment strongly
increases ratios of both CD8 and CD4 T cells to Treg and
MDSC in peritoneal lavage
To understand the apparent synergy between TIM-3
blockade and CD137 activation in the ID8 tumor model,
we sought to dissect the effects of single or combined
mAb on tumor-infiltrating immune cells (TIIC) in peri-
toneal lavage. Single CD137 engagement promoted the
prominent infiltration of CD8 T cells in peritoneal cavity,
but unchanged the relative fraction of CD4+ T cells
Figure 1 Antitumor effects of individual or combined anti-TIM-3 and anti-CD137 mAbs in murine ID8 ovarian cancer model. Mice (5 or
10 mice/group) transplanted i.p. with 1 × 106 ID8 cells 3 (A, C) or 10 (B, D) day before were treated thrice with 250 μg of control, anti-TIM-3,
anti-CD137 and anti-TIM-3/CD137 mAb at 4 days interval and overall survival of mice was recorded (A, B) and mean survival time of mice with
tumor growth was calculated (C, D). The experiment was repeated once with similar result. *P < 0.05, **P < 0.01, ***P < 0.001, compared with
control mAb treated mice.
Figure 2 Combined anti-TIM-3/CD137 mAb treatment induced tumor-specific long-lasting protection against ID8 ovarian cancer
requiring CD4+ and CD8+ T cells. The long-term survivors (90 days after first tumor challenge) pooled from 2 experiments were rechallenged
(3 mice/group) with ID8 cells given i.p. or s.c. or with TC1 cells transplanted s.c. (A); naive mice were transplanted with tumor cells as controls
(B). The survival of mice was recorded. C and D, Mice (5/group) treated with combined anti-TIM-3/CD137 mAb were also injected with an
anti-CD4, anti-CD8, anti-CD4/CD8, anti-NK1.1, anti-CD19, or control mAb with 250 μg of each mAb per mouse 1 day before and two days after
tumor challenge and every 5 days thereafter for the duration of the experiments. Tumor-bearing untreated mice were as negative controls (UNT).
Data are representative of 2 experiments. *P < 0.05, s.c.TC1 compared with s.c.ID8 or i.p.ID8 in A; control depletion compared with CD4, CD8 or
CD4/8 depletion in C; UNT compared with control, NK1.1 or CD19 depletion in D.
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CD8+ T-cell density significantly increased while the CD4+
T-cell levels were mildly elevated in mice receiving single
anti-CD137 mAb (Figure 3I and 3J). In contrast to anti-
CD137, blockade of TIM-3 increased the percentage of
CD4+ and CD8+ effector T-cells infiltrating the tumors with
former more pronounced (Figure 3A and 3B). Combined
treatment with both mAbs benefits from the increased
CD8+ and CD4+ effector T-cell infiltration elicited by anti-
TIM-3 and anti-CD137 respectively, resulting in the much
higher level of these effector T cells in TIIC compared with
that from control treated mice (Figure 3A and 3B).
We also assessed the effects of combined treatment on
Treg and MDSC using CD4+FoxP3+ and CD11b+GR-1+
makers respectively. While both mAbs moderately
decreased the fraction of Treg and MDSC in TIIC
(Figure 3C and 3D), CD137 activation increased absolute
numbers of Treg and MDSC, whereas TIM-3 blockade
did not (Figure 3K and 3L). Thus, combined anti-TIM-3/
CD137 treatment not only further diminish the percent-
ages of Treg and MDSC in TIIC compared with eitherFigure 3 Analysis of tumor-infiltrating immune cells (TIIC) in peritone
ID8 cells 10 day earlier were injected thrice at 4 days interval with 250 μg o
from treated mice was analyzed by flow cytometry for the percentages an
CD4+FoxP3+ Treg and CD11b+GR-1+ MDSC in peritoneal lavage are shown
each mouse. The ratios of CD8+ and CD4+ T cells to Treg and MDSC in per
representing data from each mouse. The absolute numbers of CD8+, CD4+
respectively with each dot representing data from each mouse. Data are re
**P < 0.01, ***P < 0.001.mAb alone, but also reduce the numbers of Treg and
MDSC to those achieved with anti-TIM-3 alone.
By increasing CD8 infiltration and attenuating accumu-
lation of Treg and MDSC, combined anti-TIM-3/CD137
treatment strongly increased intra-tumoral CD8 to Treg
and MDSC ratios (Figure 3E and 3F). The ratios of CD4
effector to Treg and MDSC in the peritoneal lavage were
also elevated in combined treatment, largely due to the ef-
fects of TIM-3 blockade in promoting increased CD4 infil-
tration (Figure 3G and 3H). We conclude that the
combined treatment creates higher CD8/Treg (23.75 ver-
sus 4.062, p < 0.01) and CD8/MDSC (8.911 versus 1.622,
p < 0.01) ratios than TIM-3 blockade alone, while also pro-
viding a significantly higher CD4/Treg (23.05 versus 5.860,
p < 0.05) and CD4/MDSC (8.672 versus 2.268, p < 0.05) ra-
tio compared to anti-CD137 alone. This combination of
both high CD8 and CD4 effector to Treg and MDSC ra-
tios in peritoneal cavity represents the shift of the nor-
mally suppressive tumor melieu to a more stimulatory
state which is more permissive for immune mediated
tumor destruction.al lavage from treated mice. Mice (5/group) injected i.p. with 1 × 106
f control or anti-TIM-3/CD137 mAb. Seven days later, peritoneal lavage
d numbers of various subsets of TIIC. The percentages of CD8+, CD4+,
in A, B, C and D respectively with each dot representing data from
itoneal lavage are shown in E, F, G and H respectively with each dot
, Treg and MDSC in peritoneal lavage are shown in I, J, K and L
presentative of 2 independent experiments. *P < 0.05,
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marked gene expression signature typical of Th1 immune
response
To further study the local immune effectors induced by
anti-TIM-3/CD137 treatment, we performed quantitative
RT-PCR to compare the transcription profile of 20 im-
mune gene products expressed in cells from peritoneal
lavage, which were collected 7 days after the third injec-
tion of mAb, with that of control mAb-treated mice. As
shown in Figure 4A, the Th1 transcription factors Stat4,
Eomes and Tbx21 (also called T-bet) and their target,
IFN-γ, were increased by 4–6 fold in anti-TIM-3/CD137
versus control-treated lavage cells, in contrast, the 2 mAb
combination downreguled transcription of the Th2 mole-
cules IL-4, Stat6, and GATA3 (Figure 4B). There was also
an increase of the Th1-associated chemokine/receptor
CXCL9-11/CXCR3 and a decrease of the Th2-associated
chemokine/receptor CXCL13/CXCR5 (Figure 4C), which
is concordant with the increase of Th1-type CD4+ and
CD8+ T cells in peritoneal lavage (Figure 3A and 3B). In
addition, expression of the genes associated with negative
immune regulation, including CTLA-4, PD-1, PD-L1,
TIM-3, IL-10, TGF-β and FoxP3, significantly decreased
in lavage cells from 2 mAb treated mice compared with
that from control- or single mAb-treated mice (Figure 4C);
Treatment with single mAb, in particular single anti-
CD137 mAb, moderately increased the expression of both
Th1- and Th2-associated genes in lavage cells. TheFigure 4 Immune-related gene expression in peritoneal lavage from t
data demonstrating upregulated transcription of the Th1-related molecules
Th2 molecules IL-4, Stat6, and GATA3 in 2 mAb-treated mice. B, Quantitativ
chemokine/receptor CXCL9-11/CXCR3 and decrease of the B-cell chemotac
from 2 mAb-treated mice. C, Results from quantitative RT-PCR demonstrati
was significantly decreased in cells of peritoneal lavage from 2 mAb-treate
lavage cells harvested from treated mice which were stimulated in vitro wi
*P < 0.05, **P < 0.01, ***P < 0.001, compared with control mAb- or single mcontrasting effect was seen on the expression of CTLA-4,
PD-1, PD-L1 and TIM-3 co-inhibitory molecules with
anti-CD137 mAb upregulated and anti-TIM-3 mAb
downregulated the expression of these molecules respect-
ively. Both of them decreased the expression of IL-10,
TGF-β and FoxP3 genes in lavage cells. All changes
between single mAb and control mAb did not reach statis-
tical significance. Consistent with the data from quan-
titative RT-PCR, lavage cells from 2 mAb combination
produced significantly higher level of IFN-γ while de-
creased level of IL-10 compared with that from control or
single mAb upon polyclonal stimulation (Figure 4D). The
data support a shift of the immune response toward
immune-stimulatory Th1 type by the 2 mAb treatment.
Combined anti-TIM-3/CD137 mAb treatment elicited an
antigen-specific CTL response
As ID8 cells express the mesothelin (Additional file 3:
Figure S2), a well-characterized tumor antigen [8], we
harvested splenocytes from 2 mAb and control mAb
treated mice, and the same number of splenocytes was
cultured in the presence of 10 μg/mL of H-2Db-restricted
mesothelin-specific peptide (amino acid 406–414) or con-
trol HPV-E7 peptide (amino acids 49–57) for 3 days and
assayed the culture supernatants for IFN-γ by ELISA.
Splenocytes from 2 mAb-treated mice, as compared with
control or single mAb-treated mice, secreted significantly
elevated levels of IFN-γ when stimulated with thereated and control mice with ID8 tumor. A, Quantitative RT-PCR
Tbx21, Eomes, IFN-γ and Stat4 and downregulated transcription of the
e RT-PCR data demonstrating elevation of the Th1-associated
tic chemokine/receptor CXCL13/CXCR5 in cells of peritoneal lavage
ng that mRNA for CTLA-4, PD-1, PD-L1, TIM-3, IL-10, TGF-β and FoxP3
d mice. D, IL-2 and IFN-γ production in the supernatants from pooled
th 50 ng/ml PMA and 1 μg/ml ionomycin for 6 hours prior to analysis.
Ab-treated mice.
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HPV peptide (P < 0.01; Figure 5A). We further determined
whether the splenocytes had cytotoxic activity. Splenocytes
from mice treated with anti-TIM-3/CD137 mAbs were
restimulated with UV-irradiated ID8 cells for 4 days before
CTL assays were performed using EL4 cells pulsed with
mesothelin or HPV-E7 derived peptide as target cells. As
shown in Figure 5B, splenocytes from anti-TIM-3/CD137
treated mice displayed cytotoxic activity on EL4 cell
pulsed with mesothelin but not with HPV-E7 peptide.
Pre-incubation with CD8 antibody suppressed the killing
activity (Figure 5C) and we conclude that combined anti-
TIM-3/CD137 mAbs elicited a tumor antigen-specific
CTL response mediated by CD8+ T cells. We also evalu-
ated the presence of mesothelin-specific antibodies in sera
from the 2 mAb treated long-term surviving mice by flow
cytometry using mesothelin-expressing ID8 cells as
detecting cells. Compared with sera from naïve mice, we
did not see a clear increase of fluorescence intensity from
sera from those long-term survivors (data not shown),
suggesting the absence of mesothelin-specific antibodies
in these mice.
Discussion
The antitumor efficacy of immunotherapy remains insuf-
ficient to achieve durable clinical responses in patients
with advanced EOC. In this study, we demonstrate that
combined anti-TIM-3/CD137 mAbs inhibited the out-
growth of ID8 ovarian cancer cells injected 10 days pre-
viously, resulting in the long-lasting survival of 60% of
mice while either mAb alone was ineffective in tumor
protection. The findings provide evidence that combined
TIM-3 blockade and CD137 activation may serve as a
novel immunotherapeutic option for treatment of ovar-
ian cancer.Figure 5 Mice injected with anti-TIM-3/CD137 mAb developed a tumo
ID8 cells 10 day earlier were injected thrice at 4 days interval with 250 μg o
splenocytes from treated mice were cultured in the presence or absence o
-derived peptide for 3 days and IFN-γ production in the supernatants were
days after the last mAb injection, splenocytes (5 × 106) from 3 mice were in
to analysis of antigen-specific CTL activity by CytoTox 96 Non-radioactive c
mesothelin or HPV-E7 peptide as target cells. The killing activity was also e
(C). Data were expressed as M ± SEM of triplicate wells.We next sought to understand the mechanisms under-
lying increased tumor-rejecting effect by simultaneously
removing a major brake on expansion via blockade of
the negative regulator TIM-3, while at the same time ac-
tively driving proliferation and survival through activa-
tion of the co-stimulatory receptor CD137. We found
that single TIM-3 blockade significantly increased the
percentage of CD4+ T cells and slightly elevated the per-
centage of CD8+ T cells while it had little effects on the
immunosuppressive CD4+FoxP3+ Treg, CD11b+GR-1+
MDSCs and CD19+ B cells in peritoneal lavage. On the
contrast, single CD137 activation promoted the accu-
mulation of CD8+ T cells with significantly elevated
percentage and absolute number in peritoneal lavage.
Quantitative RT-PCR data demonstrated moderately
increased IFN-γ expression although significantly in-
creased accumulation of CD8+ T cells in peritoneal cav-
ity from anti-CD137 mAb treated mice, indicating most
of CD8+ T cells were without function or immunologic-
ally ignorant as described previously [30]. This was
consistent with the lack of antitumor effect by single
anti-CD137 mAb in ID8 model, which may be due to
the concomitant expansion of Treg and MDSC by anti-
CD137 mAb. In accordance with the more pronounced
CD137 expression on CD8+ versus CD4+ T cells, mar-
ginal effect of anti-CD137 mAb on CD4+ T cells were
observed. Remarkably, combined anti-TIM-3/CD137
mAb increased the percentage and absolute number of
tumor-infiltrating CD4+ and CD8+ T cells, while at the
same time decreasing the immunosuppressive Treg and
MDSC in peritoneal lavage, which gave rise to the sig-
nificantly increased ratio of CD4+ and CD8+ T cells to
immunosuppressive cells.
Importantly, we detected a systemic antigen-specific
CD8+ T-cell mediated CTL immune response to mouser antigen-specific CTL response. A, mice injected i.p. with 1 × 106
f anti-TIM-3/CD137 mAb. Seven days after the last mAb injection,
f H-2Db-restricted mesothelin-derived peptides or control HPV-E7
assayed by ELISA. B, mice were treated as described in (A). Seven
cubated with 5 × 105 UV-irradiated ID8 cells for 4 days prior to subject
ytotoxicity assay using EL4 cells pulsed with H-2Db-restricted
valuated in the presence of anti-CD4, anti-CD8 or control antibody
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with ID8 tumors, as evidenced by mesothelin epitope-
specific IFN-γ production and cytotoxicity by CD8+ T
cells from these mice. As an endogenous non-mutated
antigen, mesothelin should be naturally tolerized against.
The induction of mesothelin-specific CD8+ CTL by anti-
TIM-3/CD137 mAb in the mesothelin-expressing ID8
model indicates that endogenous tolerance to meso-
thelin was overcome, which is consistent with previous
studies showing the presence of mesothelin-specific
humoral or cellular immune response in patients with
cancer expressing high level of mesothelin, such as pan-
creatic cancer, ovarian cancer or mesothelioma [31,32].
We did not detect mesothelin-specific antibodies in sera
harvested 90 days after tumor challenge in 2 mAb
treated mice by flow cytometry, but the presence of
these antibodies cannot be completely excluded in view
of comparatively low sensitivity of this approach and
possibly suboptimal time point for sera collection. Seri-
ally collection of sera at different time points after mAb
injection and utilization of more sensitive approaches
such as ELISA should be warrant in our future work.
The importance of CD8+ T-cell mediated CTL response
in tumor protection was supported by in vivo antibody de-
pletion experiments demonstrating depletion of CD8+ T
cells abrogated the antitumor effect of anti-TIM-3/CD137
mAb. The pivotal role of CD8+ T cells in antitumor effect
elicited by anti-TIM-3/CD137 mAb treatment is consistent
with other combined strategies involving anti-CD137
mAb, such as combined cyclophosphamide/anti-CD137
treatment [33], which has been shown to produce synergist
antitumor effects via expansion of CD8+ tumor-specific T
cells. The depletion of CD4+ T cells also decreased the
antitumor effect of 2 mAb treatment although the effect
was not as prominent as depletion of CD8+ T cells, which
may be explained by the fact that Treg depletion by CD4
antibody partially compensates a deleterious effect on ef-
fector CD4+ T cells in view of the finding that Treg cells
can be expanded by anti-CD137 antibody [34]. Our data
were concordant with a recent study showing the adminis-
tration of anti-TIM-3 mAb had a tumor-suppressing effect
in several transplantable and chemical carcinogen-induced
fibrosarcoma tumor models via CD4+ and CD8+ T-cell-
and IFN-γ-dependent mechanisms [16,35]. A recent study
also shows that TIM-3 blockade enhanced the antitumor
effects of vaccine-induced response against established B16
murine melanomas via NK cell-dependent mechanisms
[36], and this discrepancy may be possibly due to the dif-
ferent treatments and tumor microenvironments where
TIM-3 may modulate distinct immune cells and the related
signaling pathways that exist [36].
Noticeably, we did not detect the expression of galectin
9 on the tumor cells in spite of the immune enhancing ef-
fect of the anti-TIM3 mAb. This finding is contrasting tothe scenario of other inhibitory receptors, such as PD-1,
where the presence of the ligand (PD-L1) on the tumor
seems to correlate with the response to anti-PD-1 [37]. A
recent report did not detect a specific interaction between
galectin 9 and TIM-3 [38], suggesting that TIM-3 func-
tions are independent of galectin-9, which may partially
explain our finding. It warrants further explore whether
TIM-3 receives an inhibitory signal from an unidentified
molecule other than galectin-9 on tumor cells where
blockade of this interaction by anti-TIM-3 mAb elicits an
immunostimulatory effect.
Activation of the co-stimulatory receptor CD137 in the
clinic has shown promise as a therapy for advanced solid
tumors with manageable autoimmune adverse effects
when administrated at dose levels ranging from 0.3 mg
per kg to 10 mg per kg [27]. The major side effect of sys-
temic use of CD137 agonist antibody appears to be an as
yet poorly mechanistically defined inflammatory liver tox-
icity by infiltration with T cells and hematologic abnormal-
ities [39,40]. In our study, we did not observe any obvious
toxicity such as weight or hair loss in mice receiving single
or combined anti-TIM-3/CD137 mAb. Further detailed
biochemical and histological analysis of liver, spleen, bone
marrow and peripheral blood at different time points after
antibody injection should be warranted to inform any
major side effects induced by 2 mAb treatment. Recent
studies provide a rationale for local delivery of anti-CD137
mAb to treat tumor. The study from A. Palazon et al.
shows that hypoxia-inducing transcription factor-1α (HIF-
1α) in hypoxic tumors induces the expression of CD137
on TILs [41] and local intratumoral low-dose injection of
agonist anti-CD137 mAb elicited systemic tumor-specific
effector T cells capable of eradicating distant metastases.
In addition, a study performed in a murine AT3 breast
cancer model shows that combined radiotherapy and anti-
CD137 treatment upregulated the expression of CD137
on tumor-specific CD8+ CTLs [42]. Therefore, it is of
great interest to elucidate the role of CD137 expression on
TILs in our model since local delivery of anti-CD137 anti-
bodies might avoid the toxicity associated with systemic
application without compromising the antitumor effects.
In view of recent encouraging results of immunomod-
ulatory mAbs in clinic for treatment of multiple solid
tumor [43], our finding that TIM-3 blockade and CD137
activation synergistically induce a potent antitumor ef-
fect in a highly clinical relevant ID8 ovarian cancer
model should aid the design of future trials for ovarian
cancer immunotherapy.Additional files
Additional file 1: Figure S1. The typical presentation of ID8 ovarian
cancer in C57BL/6 mice. The left and right picture shows the
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http://www.translational-medicine.com/content/11/1/215macroscopic appearance of ascites and ID8 tumor mass in peritoneal
cavity of mice respectively.
Additional file 2: Table S1. Primers used in Real-Time PCR.
Additional file 3: Figure S2. The expression of mesothelin antigen in
ID8 cells. For detection of mesothelin expression on cell surface (left
histogram), ID8 cells was directly stained with PE labeled anti-mesothelin
(red line) or isotype-matched mAb (black line); for detection of
intracellular mesothelin, ID8 cells were fixed and permeabilized using
Cytofix/Cytoperm kit prior to staining with antibodies as above. The
mesothelin expression was analyzed by flow cytometry. All antibodies
were purchased from R&D system.
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